Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and ATRA in Relapsed/Refractory HL and B-NHL
NCT06484920Phase 2Recruiting
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tretinoin and pembrolizumab in Hodgkin lymphoma (HL) and B-cell non-Hodgkin lymphoma. Primary endpoint: Incidence of Adverse Events at 90 days. Started Nov 2024; status: recruiting.
02
Drugs
tretinoinpembrolizumab
03
Conditions
Hodgkin lymphoma (HL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06484920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06484920.